ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.
The 13th Annual World Congress of Drug Discovery & Development of Innovative Therapeutics takes place August 4-7, 2008 at the World Trade Center Boston and The Seaport Hotel. The Exhibition runs August 5-6.
The preeminent ion channel services company, ChanTest serves its drug
discovery and development customers with GLP safety and automated screening
assays using its library of ion channel-expressing cell lines -- the most
comprehensive in the world. Since its inception in 1998, ChanTest has
tested more than 18,000 compounds for more than 250 global pharmaceutical
and biotech companies -- helping them to achieve their drug safety and
discovery goals. ChanTest works in partnership with customers to speed the
drug-development process, save time and money, and ultimately -- to help
make better, safer drugs. Because of ChanTest's seminal role in this field,
along with the com
Copyright©2008 PR Newswire.
All rights reserved